Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can blood and skin markers predict lymphoma outcomes?

NCT ID NCT04904146

Knowledge-focused Sponsor: Lund University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This study looks at blood and skin samples from people with mycosis fungoides and Sézary syndrome, rare types of lymphoma that affect the skin. Researchers want to find biological markers that can predict how the disease will progress and how well a patient might respond to treatment. Participants provide samples over up to three years while receiving standard care. The goal is to improve personalized treatment decisions for these conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood tests and skin sample analysis (no drug or treatment is being tested)
What this could lead to
If successful, this could lead to better ways to predict how each patient's disease will progress and which treatments are most likely to work.
What could go wrong
This is an observational study, so it won't directly test a new treatment. Finding reliable biomarkers is uncertain and may take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2021

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with mycosis fungoides and Sézary syndrome (n=120) are recruited in the study. As a control group, healthy volonteers (n=20) are recruited.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-100 years * Histologically confirmed (according to the World Health Organization (WHO)/EORTC classification) MF/SS stages I-IV * WHO performance status 0 -3 * Absence of psychiatric illness or condition which could interfere with the subjects' ability to understand the requirements of the study. * Written informed consent according to International Conference on Harmonization (ICH)/(Good Clinical Practice (GCP), and Swedish regulations * No minimum or maximum required routine laboratory data Exclusion Criteria: Not applicable. No exclusion criteria are specified.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mycosis fungoides are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma Sezary syndrome skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mycosis fungoides Sezary syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lund University Hospital

    RECRUITING

    Lund, SE-221 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.